JP2020015733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020015733A5 JP2020015733A5 JP2019149672A JP2019149672A JP2020015733A5 JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5 JP 2019149672 A JP2019149672 A JP 2019149672A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polypeptide
- subject
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149672A JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149672A JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Division JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020015733A JP2020015733A (ja) | 2020-01-30 |
| JP2020015733A5 true JP2020015733A5 (cg-RX-API-DMAC7.html) | 2020-09-10 |
Family
ID=69580027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149672A Pending JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2020015733A (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| KR20250162619A (ko) * | 2023-03-20 | 2025-11-18 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041523A1 (en) * | 1995-06-12 | 1996-12-27 | Yeda Research And Development Co., Ltd. | Fgf9 as a specific ligand for fgfr3 |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| AU2005216547B2 (en) * | 2004-02-24 | 2009-03-12 | Allergan, Inc. | Botulinum toxin screening assays |
| NZ565511A (en) * | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| JP6055779B2 (ja) * | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
-
2019
- 2019-08-19 JP JP2019149672A patent/JP2020015733A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433820T2 (de) | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten | |
| US10786555B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| US20230241168A1 (en) | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof | |
| US9453067B2 (en) | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc | |
| JP2023099045A (ja) | インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法 | |
| US20240226236A9 (en) | Nerve growth factor fusion protein, preparation method and use thereof | |
| CA2634547C (en) | Stable ctla4 formulation for subcutaneous administration | |
| DK2633865T3 (en) | USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS | |
| JP2010518079A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537340A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512541A (ja) | Pd-1系キメラタンパク質を含む併用療法 | |
| JP2019151655A (ja) | 関節リウマチの治療のための可溶性cd24の使用方法 | |
| CA3128113A1 (en) | Pharmaceutical taci-fc fusion protein formulation | |
| JP2016506914A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506912A5 (cg-RX-API-DMAC7.html) | ||
| AU2024204870A1 (en) | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin | |
| JP6480154B2 (ja) | エタネルセプトの凍結乾燥製剤 | |
| AU2019364063B2 (en) | Pharmaceutical composition for treating aplastic anemia | |
| US7619066B2 (en) | IL-1ra variants | |
| KR20250048156A (ko) | 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료 | |
| JP7606173B2 (ja) | I型インターフェロンの中和型Fc融合タンパク質及びその使用 | |
| US7323444B2 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Weaver | Efficacy and safety of the anti-TNF biologic agents | |
| RU2023110696A (ru) | СПОСОБ ЛЕЧЕНИЯ IgA-НЕФРОПАТИИ С ИСПОЛЬЗОВАНИЕМ СЛИТОГО БЕЛКА TACI-FC | |
| HK40059370A (en) | Pharmaceutical composition for treating aplastic anemia |